...
search icon
juns-img

Jupiter Neurosciences, Inc. Common Stock, Common Stock

JUNS

NAQ

$0.6202

+$0

(0%)

1D

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$21.19M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
27.72K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.51 L
$19.51 H
$0.6202

About Jupiter Neurosciences, Inc. Common Stock, Common Stock

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson's disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson's disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida. more

Returns

Data is not properly formatted.

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue1.13M638.04K233.28K--[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":56.65,"profit":true},{"date":"2022-12-31","value":20.71,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit1.13M638.04K233.28K--[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":56.65,"profit":true},{"date":"2022-12-31","value":20.71,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin100.00%100.00%100.00%--[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses2.98M4.55M3.67M3.87M3.09M[{"date":"2020-12-31","value":65.52,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":80.65,"profit":true},{"date":"2023-12-31","value":85.16,"profit":true},{"date":"2024-12-31","value":68.01,"profit":true}]
Operating Income(1.85M)(3.91M)(3.43M)(3.87M)(3.09M)[{"date":"2020-12-31","value":-185159400,"profit":false},{"date":"2021-12-31","value":-390709700,"profit":false},{"date":"2022-12-31","value":-343244700,"profit":false},{"date":"2023-12-31","value":-387077100,"profit":false},{"date":"2024-12-31","value":-309128200,"profit":false}]
Total Non-Operating Income/Expense183.40K(407.02K)(2.27M)(1.13M)651.66K[{"date":"2020-12-31","value":28.14,"profit":true},{"date":"2021-12-31","value":-62.46,"profit":false},{"date":"2022-12-31","value":-347.63,"profit":false},{"date":"2023-12-31","value":-173.58,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(1.65M)(4.20M)(4.96M)(4.78M)(2.44M)[{"date":"2020-12-31","value":-165469900,"profit":false},{"date":"2021-12-31","value":-420025900,"profit":false},{"date":"2022-12-31","value":-495758000,"profit":false},{"date":"2023-12-31","value":-478368900,"profit":false},{"date":"2024-12-31","value":-243962500,"profit":false}]
Income Taxes-179.17K---[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes-(4.38M)---[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-437942700,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(1.65M)(4.20M)(4.96M)(4.78M)(2.44M)[{"date":"2020-12-31","value":-165469900,"profit":false},{"date":"2021-12-31","value":-420025900,"profit":false},{"date":"2022-12-31","value":-495758000,"profit":false},{"date":"2023-12-31","value":-478368900,"profit":false},{"date":"2024-12-31","value":-243962500,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(1.65M)(4.38M)(4.96M)(4.78M)(2.44M)[{"date":"2020-12-31","value":-165469900,"profit":false},{"date":"2021-12-31","value":-437942700,"profit":false},{"date":"2022-12-31","value":-495758000,"profit":false},{"date":"2023-12-31","value":-478368900,"profit":false},{"date":"2024-12-31","value":-243962500,"profit":false}]
EPS (Diluted)----(0.05)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-4.61,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

JUNS
Cash Ratio 1.88
Current Ratio 2.31

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

JUNS
ROA (LTM) 0.00%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

JUNS
Debt Ratio Lower is generally better. Negative is bad. 0.33
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.67

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

JUNS
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.00
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Jupiter Neurosciences, Inc. Common Stock share price today?

Jupiter Neurosciences, Inc. Common Stock (JUNS) share price today is $0.6202

Can Indians buy Jupiter Neurosciences, Inc. Common Stock shares?

Yes, Indians can buy shares of Jupiter Neurosciences, Inc. Common Stock (JUNS) on Vested. To buy Jupiter Neurosciences, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in JUNS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Jupiter Neurosciences, Inc. Common Stock be purchased?

Yes, you can purchase fractional shares of Jupiter Neurosciences, Inc. Common Stock (JUNS) via the Vested app. You can start investing in Jupiter Neurosciences, Inc. Common Stock (JUNS) with a minimum investment of $1.

How to invest in Jupiter Neurosciences, Inc. Common Stock shares from India?

You can invest in shares of Jupiter Neurosciences, Inc. Common Stock (JUNS) via Vested in three simple steps:

  • Click on Sign Up or Invest in JUNS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Jupiter Neurosciences, Inc. Common Stock shares
What is Jupiter Neurosciences, Inc. Common Stock 52-week high and low stock price?

The 52-week high price of Jupiter Neurosciences, Inc. Common Stock (JUNS) is $19.51. The 52-week low price of Jupiter Neurosciences, Inc. Common Stock (JUNS) is $0.51.

What is Jupiter Neurosciences, Inc. Common Stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Jupiter Neurosciences, Inc. Common Stock (JUNS) is 0.00

What is the Market Cap of Jupiter Neurosciences, Inc. Common Stock?

The market capitalization of Jupiter Neurosciences, Inc. Common Stock (JUNS) is $21.19M

What is Jupiter Neurosciences, Inc. Common Stock’s stock symbol?

The stock symbol (or ticker) of Jupiter Neurosciences, Inc. Common Stock is JUNS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top